Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

被引：0

作者：

Sifat Sharmin

Mathilde Lefort

Johanna Balslev Andersen

Emmanuelle Leray

Dana Horakova

Eva Kubala Havrdova

Raed Alroughani

Guillermo Izquierdo

Serkan Ozakbas

Francesco Patti

Marco Onofrj

Alessandra Lugaresi

Murat Terzi

Pierre Grammond

Francois Grand’Maison

Bassem Yamout

Alexandre Prat

Marc Girard

Pierre Duquette

Cavit Boz

Maria Trojano

Pamela McCombe

Mark Slee

Jeannette Lechner-Scott

Recai Turkoglu

Patrizia Sola

Diana Ferraro

Franco Granella

Julie Prevost

Davide Maimone

Olga Skibina

Katherine Buzzard

Anneke Van der Walt

Bart Van Wijmeersch

Tunde Csepany

Daniele Spitaleri

Steve Vucic

Romain Casey

Marc Debouverie

Gilles Edan

Jonathan Ciron

Aurélie Ruet

Jérôme De Sèze

Elisabeth Maillart

Hélène Zephir

Pierre Labauge

Gilles Defer

Christine Lebrun-Frénay

Thibault Moreau

Eric Berger

机构：

[1] University of Melbourne,CORe, Department of Medicine

[2] Rennes University,The Danish Multiple Sclerosis Registry, Department of Neurology

[3] EHESP,Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine

[4] REPERES,Division of Neurology, Department of Medicine

[5] EA,Department of Medical and Surgical Sciences and Advanced Technologies

[6] Univ Rennes,Multiple Sclerosis Center

[7] CHU Rennes,Department of Neuroscience, Imaging, and Clinical Sciences

[8] Inserm,Dipartimento di Scienze Biomediche e Neuromotorie

[9] CIC 1414 (Centre d’Investigation Clinique de Rennes),Medical Faculty

[10] University of Copenhagen,Nehme and Therese Tohme Multiple Sclerosis Center

[11] Charles University in Prague and General University Hospital,Department of Basic Medical Sciences, Neuroscience and Sense Organs

[12] Amiri Hospital,College of Medicine and Public Health

[13] Hospital Universitario Virgen Macarena,School of Medicine and Public Health

[14] Dokuz Eylul University,Department of Neurology, John Hunter Hospital

[15] GF Ingrassia,Department of Neuroscience

[16] University of Catania,Department of Medicine and Surgery

[17] University G. d’Annunzio,Department of Emergency and General Medicine

[18] IRCCS Istituto delle Scienze Neurologiche di Bologna,Neurology Unit

[19] Università di Bologna,Department of Neuroscience

[20] 19 Mayis University,Department of Neurology

[21] CISSS Chaudière-Appalache,Central Clinical School

[22] Neuro Rive-Sud,Department of Neurology, Faculty of Medicine

[23] American University of Beirut Medical Center,Neurophysiology Department

[24] CHUM MS Center and Universite de Montreal,Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro

[25] KTU Medical Faculty Farabi Hospital,inflammation, Hôpital Neurologique Pierre Wertheimer

[26] University of Bari,Department of Neurology

[27] University of Queensland,Department of Neurology

[28] Royal Brisbane and Women’s Hospital,Neurocentre Magendie

[29] Flinders University,Department of Neurology

[30] University Newcastle,Département de neurologie

[31] Hunter New England Health,MS Unit

[32] Haydarpasa Numune Training and Research Hospital,Department of Neurology, CHU de Caen, MS Expert Centre

[33] Azienda Ospedaliera Universitaria,Department of Neurology

[34] University of Parma,Department of Neurology

[35] Parma University Hospital,Department of Neurology

[36] CSSS Saint-Jérôme,Department of Neurology

[37] Garibaldi Hospital,Department of Neurology

[38] Monash University,Department of Neurology

[39] The Alfred Hospital,Department of Neurology

[40] Monash University,Department of Neurology

[41] Rehabilitation and MS-Centre Overpelt and Hasselt University,Department of Neurology

[42] University of Debrecen,Department of Neurology

[43] Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino,Department of Neurology

[44] Westmead Hospital,Department of Neurology

[45] Université de Lyon,CRC SEP and Department of Neurology

[46] Université,Department of Neurology

[47] Hospices Civils de Lyon,Department of Neurology

[48] Observatoire Français de la Sclérose en Plaques,Department of Neurology

[49] Centre de Recherche en Neurosciences de Lyon,Department of Neurology

[50] INSERM 1028 et CNRS UMR 5292,Department of Neurology

来源：

CNS Drugs | 2021年 / 35卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1217 / 1232

页数：15

共 50 条

[1] Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
Sharmin, Sifat
Lefort, Mathilde
Andersen, Johanna Balslev
Leray, Emmanuelle
Horakova, Dana
Havrdova, Eva Kubala
Alroughani, Raed
Izquierdo, Guillermo
Ozakbas, Serkan
Patti, Francesco
Onofrj, Marco
Lugaresi, Alessandra
Terzi, Murat
Grammond, Pierre
Grand'Maison, Francois
Yamout, Bassem
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Boz, Cavit
Trojano, Maria
McCombe, Pamela
Slee, Mark
Lechner-Scott, Jeannette
Turkoglu, Recai
Sola, Patrizia
Ferraro, Diana
Granella, Franco
Prevost, Julie
Maimone, Davide
Skibina, Olga
Buzzard, Katherine
Van der Walt, Anneke
Van Wijmeersch, Bart
Csepany, Tunde
Spitaleri, Daniele
Vucic, Steve
Casey, Romain
Debouverie, Marc
Edan, Gilles
Ciron, Jonathan
Ruet, Aurelie
De Seze, Jerome
Maillart, Elisabeth
Zephir, Helene
Labauge, Pierre
Defer, Gilles
Lebrun-Frenay, Christine
Moreau, Thibault
Berger, Eric
CNS DRUGS, 2021, 35 (11) : 1217 - 1232
[2] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis: a subgroup analysis from three international cohorts
Sharmin, S.
McCombe, P.
Slee, M.
Lechner-Scott, J.
Skibina, O.
Buzzard, K.
van der Walt, A.
Vucic, S.
Butzkueven, H.
Kalincik, T.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (4_SUPPL) : 8 - 9
[3] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis: a subgroup analysis from three international cohorts
Sharmin, S.
McCombe, P.
Slee, M.
Lechner-Scott, J.
Skibina, O.
Buzzard, K.
van der Walt, A.
Vucic, S.
Butzkueven, H.
Kalincik, T.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 : 8 - 9
[4] Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts
Sharmin, Sifat
Lefort, Mathilde
Andersen, Johanna Balslev
Leray, Emmanuelle
Horakova, Dana
Havrdova, Eva
Alroughani, Raed
Ayuso, Guillermo Izquierdo
Ozakbas, Serkan
Patti, Francesco
Onofrj, Marco
Lugaresi, Alessandra
Terzi, Murat
Grammond, Pierre
Grand'Maison, Francois
Yamout, Bassem
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Boz, Cavit
Trojano, Maria
McCombe, Pamela
Slee, Mark
Lechner-Scott, Jeannette
Turkoglu, Recai
Sola, Patrizia
Ferraro, Diana
Granella, Franco
Prevost, Julie
Maimone, Davide
Skibina, Olga
Buzzard, Katherine
Van der Walt, Anneke
Van Wijmeersch, Bart
Csepany, Tunde
Spitaleri, Daniele Litterio A.
Vucic, Ostoja
Casey, Romain
Debouverie, Marc
Edan, Gilles
Ciron, Jonathan
Ruet, Aurelie
De Seze, Jerome
Maillart, Elisabeth
Zephir, Helene
Labauge, Pierre
Defer, Gilles
Lebrun-Frenay, Christine
Moreau, Thibault
Berger, Eric
NEUROLOGY, 2021, 96 (15)
[5] Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Kalincik, Tomas
Horakova, Dana
Spelman, Tim
Jokubaitis, Vilija
Trojano, Maria
Lugaresi, Alessandra
Izquierdo, Guillermo
Rozsa, Csilla
Grammond, Pierre
Alroughani, Raed
Duquette, Pierre
Girard, Marc
Pucci, Eugenio
Lechner-Scott, Jeannette
Slee, Mark
Fernandez-Bolanos, Ricardo
Grand'Maison, Francois
Hupperts, Raymond
Verheul, Freek
Hodgkinson, Suzanne
Oreja-Guevara, Celia
Spitaleri, Daniele
Barnett, Michael
Terzi, Murat
Bergamaschi, Roberto
McCombe, Pamela
Sanchez-Menoyo, Jose
Simo, Magdolna
Csepany, Tunde
Rum, Gabor
Boz, Cavit
Havrdova, Eva
Butzkueven, Helmut
ANNALS OF NEUROLOGY, 2015, 77 (03) : 425 - 435
[6] ECONOMIC EVALUATION OF NATALIZUMAB VERSUS FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SWEDEN
Alexopoulos, S. T.
Deniz, B.
Walker, A. R.
Arnold, R.
Bates, D.
VALUE IN HEALTH, 2012, 15 (04) : A145 - A145
[7] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
Cavit Boz
Serkan Ozakbas
Murat Terzi
Rana Karabudak
Serhan Sevim
Recai Turkoglu
Aysun Soysal
Belgin Petek Balcı
Hüsnü Efendi
Ömer Faruk Turan
Nur Yüceyar
Mehmet Fatih Yetkin
Serap Zengin Karahan
Meltem Demirkıran
Sibel Guler
Kadriye Agan
Nefati Kıylıoğlu
Cavid Baba
Asli Tuncer
Mesrure Köseoğlu
Neurological Sciences, 2023, 44 : 2121 - 2129
[8] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
Boz, Cavit
Ozakbas, Serkan
Terzi, Murat
Karabudak, Rana
Sevim, Serhan
Turkoglu, Recai
Soysal, Aysun
Balci, Belgin Petek
Efendi, Husnu
Turan, Omer Faruk
Yuceyar, Nur
Yetkin, Mehmet Fatih
Karahan, Serap Zengin
Demirkiran, Meltem
Guler, Sibel
Agan, Kadriye
Kiylioglu, Nefati
Baba, Cavid
Tuncer, Asli
Koseoglu, Mesrure
NEUROLOGICAL SCIENCES, 2023, 44 (06) : 2121 - 2129
[9] Natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis: a prospective observational study of 197 patients
Baroncini, D.
Ghezzi, A.
Stefanin, C.
Zaffaroni, M.
Annovazzi, P.
Baldini, S.
Comi, G.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 191 - 192
[10] Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
Lorscheider, Johannes
Benkert, Pascal
Lienert, Carmen
Hanni, Peter
Derfuss, Tobias
Kuhle, Jens
Kappos, Ludwig
Yaldizli, Ozgur
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (06) : 777 - 785

← 1 2 3 4 5 →